Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 31Neoplasms 9Neoplasm Metastasis 5Colorectal Neoplasms 3Wilms Tumor 2Skin Neoplasms 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Skin Diseases 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Medulloblastoma 1Lymphoma 1

Interventions

Ipilimumab 10tremelimumab 6durvalumab 5Nivolumab 3pembrolizumab 2tilsotolimod 1spartalizumab 1relatlimab 1folfirinox 1balstilimab 1Vemurafenib 1Vaccines 1Radiotherapy 1Radiofrequency Ablation 1Radiation 1Paclitaxel 1Oxaliplatin 1Opdualag 1Melphalan 1Leucovorin 1Fluorouracil 1Docetaxel 1Cryosurgery 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Diabetes Mellitus, Insulin-Dependent, 12 × Vemurafenib × Clear all
NCT03013491 2025-06-17

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

CytomX Therapeutics

Phase 1/2 Terminated
196 enrolled 28 charts
Lymphoid

Diabetes Mellitus, Insulin-Dependent, 12, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡